Genenta CEO Paracchi Acquires 30,000 ADS, Holding Reaches 10% Ownership
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 19 2025
0mins
Source: Newsfilter
- Stock Acquisition: Genenta Science CEO Pierluigi Paracchi has acquired a total of 30,000 American Depositary Shares (ADS) through open-market purchases, bringing his total holdings to 2,326,129 shares, which represents approximately 10% of the company's outstanding shares, reflecting confidence in the company's future prospects.
- Market Signal: Paracchi's acquisition was made without any reported sales, indicating his optimistic outlook on Genenta's long-term value, which may enhance investor trust and potentially have a positive impact on the stock price.
- Clinical Progress: Genenta is conducting a Phase 1 trial for newly diagnosed Glioblastoma Multiforme (GBM) patients, with preliminary results suggesting that its treatment may effectively reprogram the tumor microenvironment and enhance immune responses, further solidifying the company's position in the oncology immunotherapy market.
- Future Outlook: The company has also initiated a Phase 1/2a clinical study for metastatic Renal Cell Carcinoma, in combination with immune checkpoint inhibitors, which, if successful, could significantly enhance the competitiveness of its treatment options and drive growth in the biopharmaceutical sector.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on GNTA
Wall Street analysts forecast GNTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNTA is 7.00 USD with a low forecast of 7.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.350
Low
7.00
Averages
7.00
High
7.00
Current: 1.350
Low
7.00
Averages
7.00
High
7.00

No data
About GNTA
Genenta Science SpA is an Italy-based company engaged in clinical-stage biotechnology research. The Company focuses on the development of lentivirus-based gene and cell therapies in cancer. It uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The Company not only operates locally but also is present in global markets, including the United States.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Genenta Science Transitions to Defense Sector Consolidator
- Strategic Shift: Genenta Science announced its rebranding to Saentra Forge S.p.A. and plans to acquire privately held businesses with approximately €5 million in EBITDA, marking a strategic pivot towards the defense sector.
- Funding Commitment: The company has entered into an agreement to provide €5.1 million in funding to ATC, which is projected to achieve around €4 million in revenue by 2026 and double its EBITDA by 2027, highlighting the growth potential of this new direction.
- Clinical Milestones: Genenta has reached key clinical milestones aimed at establishing partnerships with major pharmaceutical and biotech firms to accelerate development, improve market access, and enhance strategic value.
- Financial Outlook: Despite a 68.29% decline in stock over the past year, shares are currently trading 87.5% above the 20-day simple moving average, indicating short-term strength, with expectations of cash and equivalents reaching approximately $33 million by the end of 2025.

Continue Reading
Biomx Inc Shares Surge After 13D Filing Reveals Major Stake
- Stake Increase: Pyu Pyu Capital disclosed a 19.99% stake in Biomx Inc through a 13D filing, causing the company's shares to surge 103.4% to $8.34 in pre-market trading, indicating strong market confidence in its future prospects.
- Market Reaction: The dramatic rise in Biomx Inc's stock price reflects optimistic investor expectations regarding its potential growth opportunities, particularly in the context of strategic transformations within the biotechnology sector, which may attract further investor interest.
- Industry Impact: The significant increase in Biomx Inc's stock price could positively influence other biotechnology companies, enhancing overall market confidence in the sector and potentially leading to increased capital inflows into related fields.
- Investor Sentiment: This substantial stock price increase not only elevates Biomx Inc's market position but may also encourage other companies to adopt similar strategic initiatives to attract investors and enhance their competitive edge.

Continue Reading





